GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)

Phase 2

Completed

• Conditions: Anxiety Disorder

• Registration Number: NCT00546624
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

This study will determine the effectiveness of MK0777 GEM versus Lorazepam in the treatment of patients with generalized anxiety disorder.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Detailed Description

Not available

Study Timeline

• Study Start: 2002-11
• Primary Completion: 2003-02
• Study Completion: 2003-02
• Study First Submitted: 2007-10-17
• Study First Submitted QC: 2007-10-17
• Study First Posted: 2007-10-19
• Status Verified: 2015-10
• Last Update Submitted: 2015-10-30
• Last Update Posted: 2015-11-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

• Have been diagnosed with Generalized Anxiety Disorder
• Women of childbearing potential must use a double-barrier methods of contraception and must have a negative blood pregnancy test at the beginning of the study

Read More

Exclusion Criteria

• History of drug or alcohol abuse
• Have previously participated in another study using MK0777

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL